Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
C-reactive protein (CRP), an important inflammatory factor, plays an essential role in the pathogenesis of atherosclerosis.
|
30146678 |
2019 |
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
LHGDN |
High-sensitivity C-reactive protein is independently associated with early carotid artery progression in women but not in men: the INVADE Study.
|
17885262 |
2007 |
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Previous studies focused on the effects of CRP on ischaemic heart failure and atherosclerosis.
|
19343415 |
2009 |
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
We investigated effects of cholesterol lowering by therapeutic intervention (2 years) with atorvastatin (80 mg daily) and simvastatin (40 mg daily) on circulating oxidized LDL (absolute level and in proportion to plasma apolipoprotein B) in relation to atherosclerosis progression (carotid intima-media thickness, carotid IMT) and to inflammation (high-sensitivity C-reactive protein, hsCRP) in 115 stable patients with heterozygous familial hypercholesterolemia (FH).
|
16005883 |
2006 |
Atherosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
CRP gene single nucleotide polymorphisms (SNPs) have been shown to be associated with CRP concentration; however, their independent effect on atherosclerosis has not been yet established.
|
19428053 |
2009 |
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Type 2 diabetes (T2D) (OR 4.50, 95%CI 1.74-11.62, p = 0.002), high blood pressure (OR 2.03, 95%CI 1.04-4.14, p = 0.042), ACPA (OR 2.36, 95%CI 1.19-4.69, p = 0.014) and mean values of CRP during the follow-up (OR 1.07, 95%CI 1.03-1.14, p = 0.040) were significantly associated with higher risk of subclinical atherosclerosis.
|
31481105 |
2019 |
Atherosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
B-mode carotid ultrasound was performed among 3330 healthy adults in the CVDFACT cohort study, and the genetic effects of atherosclerosis-related genes including connexin37 (GJA4), C-reactive protein (CRP), paraoxonase (PON1), adiponectin (ACDC), angiotensin-converting enzyme (ACE), beta-adrenergic receptor (ADRB1, ADRB2), antithrombin III (SERPINC1), and kinesin family member 6 (KIF6) were evaluated by a multivariate regression model, adjusting for traditional vascular risk factors.
|
21044781 |
2011 |
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
LHGDN |
For clinicians plasma C-reactive protein (CRP) levels are the only widely available tests that provide a tangible link between inflammation and atherosclerosis.
|
15306744 |
2004 |
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Plasma C-reactive protein, genetic risk score, and risk of common cancers in the Atherosclerosis Risk in Communities study.
|
24036889 |
2013 |
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Elevated baseline levels of acute-phase proteins such as C-reactive protein (CRP) or cytokines like interleukin-6 (IL-6) are known risk factors for atherosclerosis and cardiovascular disease (CVD) events.
|
16900203 |
2006 |
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
The results suggest that maternal type 1 diabetes increases the foetal plasma LDL cholesterol and CRP concentration and thus might predispose the offspring to development of atherosclerosis.
|
18551710 |
2008 |
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
The observed association between CRP and atherosclerosis might simply be reverse causation: atherosclerotic disease progression induces CRP.
|
28930598 |
2018 |
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Enzymatically modified low density lipoprotein (eLDL), C reactive protein (CRP), dendritic cells (DCs), and T cells were shown to be involved in the pathogenesis of atherosclerosis.
|
28433861 |
2018 |
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
C-reactive protein promotes atherosclerosis by increasing LDL transcytosis across endothelial cells.
|
24517733 |
2014 |
Atherosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We hypothesized that the CYP2C9(*)2 (rs.1799853) and CYP2C9(*)3 (rs.1057910) polymorphisms with decreased enzyme activity affect risk of subclinical atherosclerosis (reduced ankle brachial index and increased C-reactive protein), ischemic vascular diseases (ischemic heart disease, myocardial infarction, ischemic cerebrovascular disease and ischemic stroke) and death after an ischemic heart disease diagnosis.
|
19652664 |
2009 |
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Besides its role in the humoral innate immune response, CRP contributes to cardiovascular disease progression by recognizing and binding multiple intrinsic ligands. mCRP is not present in the healthy vessel wall but it becomes detectable in the early stages of atherogenesis and accumulates during the progression of atherosclerosis.
|
29552019 |
2018 |
Atherosclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Since a crosstalk between AGE and angiotensin II (Ang II) has been proposed in the pathogenesis of accelerated atherosclerosis in diabetes, we examined here whether and how telmisartan, a unique Ang II type 1 receptor blocker (ARB) with peroxisome proliferator-activated receptor-gamma (PPAR-gamma)-modulating activity, could inhibit AGE-induced CRP expression in a human hepatoma cell line, Hep3B cells.
|
17004092 |
2006 |
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
After being considered a marker of acute inflammation for several decades and fruitfully used in clinical practice, CRP has been recently considered as a potential contributor to inflammatory diseases including atherosclerosis as well as a marker of cardiovascular risk.
|
17584094 |
2007 |
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
These results suggest that there is a link between plasma CRP and the degree of atherosclerosis and that inhibition of plasma CRP may represent a therapeutic modality for the treatment of cardiovascular disease.
|
16192648 |
2005 |
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
In CANTOS, the magnitude of benefit of this cytokine-targeted approach to atherosclerosis treatment was associated to the magnitude of reduction of the central signaling cytokine IL-6 and the downstream clinical biomarker high-sensitivity CRP (C-reactive protein).
|
30702995 |
2019 |
Atherosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
-717A>G polymorphism of human C-reactive protein gene associated with coronary heart disease in ethnic Han Chinese: the Beijing atherosclerosis study.
|
15517131 |
2005 |
Atherosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Association of plasma fibrinogen, C-reactive protein and G-455>A polymorphism with early atherosclerosis in the VITA Project cohort.
|
21136015 |
2011 |
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
By contrast, only 3 of 18 internal mammary and 4 of 12 radial arteries with virtually no atherosclerosis were positive for CRP mRNA.
|
12975260 |
2003 |
Atherosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The aim of this study was to investigate whether they were altered in Chinese populations with various risk factors for atherosclerosis and their potential associations with C-reactive protein (CRP).
|
22614118 |
2012 |
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Furthermore, CRP has been claimed to play a role in the pathogenesis of atherosclerosis; therefore, CRP polymorphisms might be associated with acute myocardial infarction (AMI).
|
16803998 |
2006 |